Preview

Качественная клиническая практика

Расширенный поиск

Клинико-экономические аспекты терапии болезни Альцгеймера в России

Полный текст:

Аннотация

Экселон ТТС обладает необходимыми клинико-экономическими характеристиками для включения в государственные программы лечения деменции. Он превосходит по показателю минимизации затрат Реминил (галантамин) и Акатинол (мемантина гидрохлорид), включенные в программу государственного возмещения. Суммируя экономичность с определенными клиническими позитивными преимуществами Экселона ТТС, можно сделать вывод о необходимости предпочтения Экселона ТТС для фармакотерапии болезни Альцгеймера.

Об авторах

Ю. Б. Белоусов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Россия


С. К. Зырянов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Россия


Д. Ю. Белоусов
ООО "Центр фармакоэкономических исследований", г. Москва
Россия


А. С. Бекетов
ООО "Центр фармакоэкономических исследований", г. Москва
Россия


Список литературы

1. .Бачурин С.О. Медико-химические подходы к направленному поиску препаратов для лечения и предупреждения болезни Альцгеймера . // Вопросы медицинской химии, 2001, №2 . Эл . версия доступна на www .medi .ru/pbmc/8810201 .htm

2. .Дамулин И.В. Болезнь Альцгеймера: некоторые клинические и терапевтические аспекты . Consilium Medicum 2004; T6 (№8):

3. .Елагин Е.И. Переносимость и безопасность ингибиторов холинэстеразы в лечении деменции . Consilium Medicum 2005; T7 (№2)

4. .Захаров В.В., Яхно Н.Н. Нарушения памяти . М .: Гэотар-Мед, 2003 .

5. .Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2008 Revision, http:// esa .un .org/unpp,, Sunday, May 03, 2009 .

6. .Здравоохранение в России: Стат .сб ./ Госкомстат России . М ., 2001 . — 356 с

7. .Калын Я.Б. Клиника инициальных проявлений и особенности последующего течения сенильной деменции//Дис . . . .канд . мед . наук . М ., 1990; 220

8. .Калын Я.Б., Брацун А.Л. Деменции альцгеймеровского типа: эпидемиология и факторы риска // Психиатрия и психофармакотерапия 2001; 2

9. .Коршунов А.М., Преображенская И.С. Неврол . журн . 1998; 3 (1): 40–6

10. .Прейскурант на оказание медицинских услуг ММА им . Сеченова, г . Москвы, 2009 г .

11. .Российский статистический ежегодник, 2004 .

12. .Российский статистический ежегодник . 2006: Стат .сб/Росстат . — М ., 2006 . — 806 с .

13. .Численность населения Российской Федерации по полу и возрасту на 1 января 2006 года . Статистический бюллетень . Росстат . — М ., 2006

14. .Численность населения Российской Федерации по полу и возрасту на 1 января 2005 года . Статистический бюллетень . Росстат . — М ., 2005

15. .Численность населения Российской Федерации по полу и возрасту на 1 января 2004 года . Статистический бюллетень . Росстат . — М ., 2004

16. .Яхно Н.Н., Захаров В.В. Невролог . журн . 1997; 4: 4–9

17. .Adler G., Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients . Neuropsychobiology . 2001; 43 (4): 273-276

18. .Aguglia E., Onor M.L., Saina M., Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting // Curr Med Res Opin . 2004;20 (11): 1747-1752

19. .Amici S., Lanari A., Romani R., Antognelli C., Gallai V., et al. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina . Mechanisms of Ageing and Development . 2001; 122 (16): 2057-2062

20. .Arai M. Parkinsonism onset in a patient concurrently using tiapride and donepezil . Internal Medicine . 2000; 39 (10): 863

21. .Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development—a study of molecular forms . Neurochemistry International . 1992; 21: 381 –396

22. .Areosa S.A., Sherriff F. Memantine for dementia . Cochrane Database of Systematic Reviews 2003; (1): CD003154 . Review . Update in: Cochrane Database Syst Rev . 2003;(3):CD003154

23. .Ballard C.G. Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition . European Neurology . 2002; 47: 64 –70

24. .Barner E.L., Gray S.L. Donepezil use in Alzheimer disease . Annals of Pharmacotherapy . 1998; 32 (1): 70-77 .

25. .Birks J., Flicker L. Selegiline for Alzheimer’s disease . Cochrane Database of Systematic Reviews . 2003; (1): CD000442

26. .Birks J., Grimley Evans J., Iakovidou V., Tsolaki M. Rivastigmine for Alzheimer’s disease . Cochrane Database Systematic Review . 2000; (4): CD001191

27. .Birks J.S., Harvey R. Donepezil for dementia due to Alzheimer’s disease . Cochrane Database of Systematic Reviews 2003; (3): CD001190

28. .Bouman W.P., Pinner G. Violent behavior-associated with donepezil . American Journal of Psychiatry . 1998; 155 (11): 1626-1627 .

29. .Bourke D., Druckenbrod R.W. Possible association between donepezil and worsening Parkinson’s disease . Annals of Pharmacotherapy . 1998; 32 (5): 610-611

30. .Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series . Current Medical Research and Opinion . 2002; 18 (5): 258-264

31. .Burns A., Rossor M., Hecker J., Gauthier S., Petit H., et al. The effects of donepezil in Alzheimer’s disease — results from a multinational trial . Dementia and Geriatric Cognitive Disorders . 1999; 10 (3): 237-244

32. .Calvo-Romero J.M., Ramos-Salado J.L. Symptomatic sinus bradycardia associated with donepezil . Revista de Neurologia . 1999; 28 (11): 1070-1072

33. .Canadian Adverse Drug Reaction Monitoring Program . Donepezil: suspected adverse reactions . Canadian Medical Association Journal 1998; 159:81

34. .Coelho F., Birks J. Physostigmine for Alzheimer’s disease // Cochrane Database of Systematic Reviews 2001; (2): CD001499 .

35. .Cummings J.L., Kaufer D. Neuropsychiatric aspects of Alzheimer‘s disease: the cholinergic hypothesis revisited . Neurology . 1996; 47 (4): 876-883 .

36. .Cummings JL. In: Alzheimer’s Disease . Treatment and Long-Term Management . Ed . by J .L .Cummings, B .L .Miller . New York, Basel: Marcel Dekker, Inc ., 1990; P . 3–19 .

37. .Cutler N.R., Polinsky R.J., Sramek J.J., Enz A., Jhee S.S., et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease . Acta Neurologica Scandinavica . . 1998; 97 (4): 244-250

38. .Davidsson P., Blennow K., Andreasen N., Eriksson B., Minthon L., et al. Differential increase in cerebrospinal fluid–acetylcholinesterase after treatment with acetyl-cholinesterase inhibitors in patients with Alzheimer’s disease . Neuroscience Letter .2001; 300: 157 –160

39. .Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer’s disease . Lancet .1976; 2: 1403

40. .Dunn N.R., Pearce G.L., Shakir S.A. Adverse effects associated with the use of donepezil in general practice in England . Journal of Psychopharmacology 2000; 14 (4): 406-408

41. .Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease . Progress in Brain Research . 1993; 98: 431-438

42. .Enz A., Boddeke H., Gray J., Spiegel R. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor . Annals of the N-Y Academy of Sciences . 1991; 640: 272-275

43. .Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial . Lancet . 2002; 359 (9314): 1283-1290

44. .Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer’s Disease and related dementias: a 26-week follow-up . Internal Psychogeriatrics 2001; 13 (Suppl 2): 241

45. .Evans D.A., Funkenstein H.H., Albert M.S., et al. Prevalence of Alzheimer’s Disease in a community population of older person Higher than previously reported // JAMA, 1989; 262: 2551-2556

46. .Farlow M.R. Do cholinesterase inhibitors slow progression of Alzheimer’s disease? International Journal of Clinical Practice 2002; Suppl (127): 37-44

47. .Fioravanti M., Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment // Cochrane Database of Systematic Reviews . 2001; (4): CD003159

48. .Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly . Cochrane Database of Systematic Review . 2005 18; (2): CD000269

49. .Flicker L., Grimley Evans J. Piracetam for dementia or cognitive impairment . Cochrane Database of Systemqtic Review . 2000; (2): CD001011 . Update in: Cochrane Database of Systemativ Review . 2001; (2): CD001011

50. .Fraser M., Snyder E.H. Jr. The economic benefits of delaying progression in Alzheimer’s Disease using cholinesterase inhibitors . Clinical Geriatrics . 2000; 8 (2): 1-12

51. .Giacobini E. Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy . In: Giacobini E ., Ed . Cholonesterases and cholinesterase inhibitors . London: Martin Dunitz Ltd, 2000: 181-226

52. .Giladi N., Shabtai H., Gurevich T., Benbunan B., Anca M., Korczyn A.D. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease . Acta Neurologica Scandinavica . 2003; 108 (5): 368-373

53. .Glennie J., for the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) . Review: Tacrine has limited efficacy for Alzheimer disease» . ACP J Club 1997;128:46 . Перевод представлен на http://www .mediasphera .aha .ru/mjmp/98/5/r5-98-5 .htm

54. .Grace J., Daniel S., Stevens T., Shankar K.K., Walker Z., et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial . International Psychogeriatrics . 2001; 13 (2): 199-205

55. .Greenberg S.M., Tennis M.K., Brown L.B., Gomez-Isla T., Hayden D.L., et al. Donepezil therapy in clinical practice: a randomized crossover study . Archives of Neurology . 2000; 57 (1): 94-99

56. .Greig N.H., Utsuki T., Yu Q., Zhu X., Holloway H.W., et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase [review] . Current Medical Research and Opinion . 2001; 17: 159 –165

57. .Grossberg G., Irwin P., Satlin A., Mesenbrink P., Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years . American Journal of Geriatric Psychiatry . 2004; 12 (4): 420-431 . Erratum in: American Journal of Geriatric Psychiatry . 2004; 12 (6): 679

58. .Grossberg G., Irwin P., Spiegel R., et al. Rivastigmine in Alzheimer’s Disease: efficacy over 2 years compared with historical controls .Poster presented at the International Psychogeriatric Association, Nice, France, 9-14 September, 2001

59. .Guillozet A., Smiley J.F., Mash D.C., Mesulam M.M. Butyrylcholinesterase in the life cycle of amyloid plaques . Annals of Neurology .1997; 42: 909 –918

60. .Hashimoto M., Imamura T., Tanimukai S., Kazui H., Mori E. Urinary incontinence: an unrecognised adverse effect with donepezil . Lancet . 2000; 356 (9229): 568

61. .Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia . // International Journal of Clinical Pharmacology 2002; Suppl . 127: 45–63 .

62. .Kanowski S., Herrmann W.M., Stephan K., et al. Proof of efficacy of the ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia . Pharmacopsychiatry 1996; 29: 47-56

63. .Kasa P., Papp H., Kasa P. Jr, Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain . Neuroscience . 2000; 101 (1): 89-100

64. .Kennedy J.S., Polinsky R.J., Johnson B., Loosen P., Enz A., et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans . Journal of Clinical Psychopharmacology . 1999; 19 (6): 513-521

65. .Kuhl D.E., Minoshima S., Frey K.A., Foster N.L., Kilbourn M.R., et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex . Annals of Neurology . 2000; 48 (3): 391-395

66. .Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors . European Journal of Neurology . 2000; 7 (2): 159-169

67. .Lane R.M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors . International Clinical Psychopharmacology . 1996; 11 ( Suppl 5): 31-61 . Review . Erratum in: International Clinical Psychopharmacology 1997; 12 (2): 126

68. .Le Bars P.L., Kieser M., Itil K.Z. A 26 week analysis of a doubleblind, placebo-controlled trial of the Ginkgo biloba extract Egb 761 in dementia . Dementia Geriatric Cognitive Disorders 2000; 11: 230-237

69. .Lehmann D.J., Johnston C., Smith A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease // Hum Mol Genet . 1997; 6 (11): 1933-1936

70. .Lehmann D.J., Nagy Z., Litchfield S., Borja M.C., Smith A.D. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer’s disease . Human Genetics . 2000; 106 (4): 447-452

71. .Li B., Stribley J.A., Ticu A., Xie W., Schopfer L.M., et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse // Journal of Neurochemistry . 2000; 75 (3): 1320-1331

72. .Lovenstone S., Gauthier S. Management of Dementia . London: Martin Dunitz, 2001 .

73. .Magnuson T.M., Keller B.K., Burke W.J. Extrapyramidal side effects in a patient treated with risperidone plus donepezil . American Journal of Psychiatry . 1998; 155 (10): 1458-1459 .

74. .Malouf R., Birks J. Donepezil for vascular cognitive impairment // Cochrane Database of Systematic Reviews 2004; (1): CD004395 .

75. .Maurer I., Zierz S., Moller H.J., Jerusalem F. Cytochrome c oxidase in Alzheimer’s disease // Neurology . 1995; 45 (7): 1423 .

76. .McRae T., Orazem J. A large-scale, open-label trial of donepezil in the treatment of Alzheimer’s Disease: side-effects and concomitant medication use . Internal Journal of Neiropharmacology 1999; 2 (Suppl 1): 176

77. .Mesulam M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain . Neurobiology of Disease .2002; 9:88 –93

78. .Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology . Drug Safety . 1998; 19 (6): 465-480 . Review . Erratum in: Drug Safety 1999; 20 (2): 146

79. .Nordberg A., Darreh-Shori T., Svensson A., Guan Z. Acetylcholinesterase and butyrylcholinesterase activities in CSF of mild AD patients following 12 months of rivastigmine treatment . Journal of neurological sciences 2001; 187 (suppl 1): P0144

80. .Nordberg A., Stefanova E., Almkvist O., et al. Improved cortical glucose metabolism in Alzheimer’s Disease patients treated with rivastigmine for 1 year . Journal of Neurology Science 2001; 187 (Suppl 1): P0142

81. .Olin J., Schneider L. Galantamine for Alzheimer’s disease . Cochrane Database of Systematic Reviews 2001; (4): CD001747 . Review . Update in: Cochrane Database of Systematic Reviews . 2002; (3):CD001747 .

82. .Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type . Neuropathology and Applied Neurobiology . 1978; 4: 273 –277

83. .Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action [review] . International Journal of Clinical Practice . 2002; Suppl . 127: 6 –19

84. .Potkin S.G., Messina J., Graham S. Safety of rivastigmine in Alzheimer’s Disease: pooled results from phase III studies . Poster presented at the World Alzheimer Congress, Washington, USA, July 9-13, 2000

85. .Prasad K.N., Cole W.C., Hovland A.R., Prasad K.C., Nahreini P., et al. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale . Current Opinion in Neurology . 1999; 12 (6): 761-770 .

86. .Pratt R. results of clinical studies with donepezil in vascular dementia . Presented at the 2nd International Congress on Vascular Dementia, Salzburg, Austria, January 24-27, 2002

87. .Qizilbash N., Birks J., Lopez-Arrieta J., Lewington S., Szeto S. Tacrine for Alzheimer’s disease . Cochrane Database Systematic Review . 2000; (2): CD000202 . Update in: Cochrane Database Systematic Review . 2000; (3): CD000202 .

88. .Raskind M., Truyn L. Galantamine has longterm cognitive benefits in Alzheimer’s Disease — an analysis of responder rates at 36 months . Poster presented at the 7th International symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, 3-6 April 2002

89. .Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension . The Galantamine USA-1 Study Group . Neurology . 2000; 54 (12): 2261-2268 .

90. .Reading P.J., Luce A.K., McKeith I.G. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial . Movement Disorders . 2001; 16 (6): 1171-1174

91. .Rockwood K., Kershaw P, on behalf of the Galanthamine International-2 Study Group . Galanthamine’s clinical benefits are not offset by sleep disturbance: a 3-month placebo-controlled study in patients with Alzheimer’s Disease . Poster presented at the World Alzheimer Congress, Washington, USA, July 9-13, 2000

92. .Rogers S.L., Cooper N.M., Sukovaty R., Pederson J.E., Lee J.N., et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses . British Journal of Clinical Pharmacology . 1998; 46 Suppl 1: 7-12

93. .Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study . Donepezil Study Group . Archives of Internal Medicine . 1998; 158 (9): 1021-1031

94. .Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease . Donepezil Study Group . Neurology . 1998; 50 (1): 136-145

95. .Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia . International Journal of Clinical Practice . 2002; Suppl (127): 20-36

96. .Rosler M., Anand R., Cicin-Sain A., et al. Safety and efficacy of rivastigmine in patients with Alzheimer’s Disease: results of an international, 26-weeks, multicenter, randomised, placebo-controlled trial // BMJ 1999; 318: 633-638

97. .Rosler M., Retz W., Retz-Junginger P., Dennler H.J. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease . Behavioural Neurology . 1998; 11 (4): 211-216

98. .Schmitt B., Bernhardt T., Moeller H.-J., Heuser I., Frolich. L. Combination therapy in Alzheimer’s Disease . CNS Drugs 2004; 18 (13): 827-844

99. .Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials // JAMA . 2005; 294 (15): 1934-1943

100. .Shepherd G., Klein-Schwartz W., Edwards R. Donepezil overdose: a tenfold dosing error . Annals of Pharmacotherapy . 1999; 33 (7-8): 812-815

101. .Shua-Haim J.R., Smith J.M., Amin S. Safety and tolerability of slow titration o rivastigmine in the treatment of patients with Alzheimer’s Disease: an overall analysis of two prospective studies . Poster presented at the American Geriatrics Society Annual Scientific Meeting: Chicago, Ilinois, 9-13 May 2001; Abstract P202

102. .Siek G.C., Katz L.S., Fishman E.B., Korosi T.S., Marquis J.K. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain . Biological Psychiatry . 1990; 27 (6): 573-580

103. .Staff R.T., Gemmell H.G., Shanks M.F., Murray A.D., Venneri A. Changes in the rCBF images of patients with Alzheimer’s disease receiving Donepezil therapy . Nuclear Medicine Communications . 2000; 21 (1): 37-41

104. .Stahl S., Markowitz J., Gutterman E. Aricept (donepezil) is associated with incresed hypnotis use among Alzheimer’s Disease patients living in the community . Poster presented in the International Psychogeriatric Association Meeting, Nice, France, 9-14 September, 2001

105. .Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD . The Galantamine USA-10 Study Group . Neurology . 2000 Jun 27;54(12):2269-76

106. .Thomsen T., Kaden B., Fischer J.P., Bickel U., Barz H., et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine . European Journal of Clinical Chemistry and Clinical Biochemistry . 1991; 29 (8): 487-492

107. .Thomsen T., Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo . Life Science . 1990; 46 (21): 1553-1558

108. .van Dongen M.C., van Rossum E., Kessels A.G., et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial . Journal of American Geriatric Society 2000; 48: 1183-1194

109. .Vellas B., Inglis F., Potkin S., et al. Interim results from an international clinical trials with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer’s Disease patients . International Journal of Geriatric Psychopharmacology 1998; 1: 140-144

110. .Venneri A., Shanks M.F., Staj R.T., et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s Disease . Neiroreport 2—2; 13: 83-96

111. .Voisin T., Reynish E., Portet F., Feldman H., Vellas B. What are the treatment options for patient with severe Alzheimer’s Disease? CNS Drugs 2004; 18 (9): 575-583

112. .Wallin A., Gottfries C.G., Karlsson I., Svennerholm L. Decreased myelin lipids in Alzheimer’s disease and vascular dementia . Acta Neurologica Scandinavica . 1989; 80 (4): 319-323 .

113. .Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer’s disease . CNS Drugs . 1999; 12 (4): 307 –323

114. .Wengel S.P., Roccaforte W.H., Burke W.J., Bayer B.L., McNeilly D.P., et al. Behavioral complications associated with donepezil . American Journal of Psychiatry . 1998; 155 (11): 1632-1623 .

115. .Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer’s disease // Hum Genet 1999; 104: 158-163

116. .Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial . Galantamine International-1 Study Group . BMJ . 2000; 321 (7274): 1445-1449 . Erratum in: BMJ 2001; 322 (7283): 405 .

117. .Wilkinson D.G., Passmore P., Smith R. et al. Comparison of the tolerability, ease of use and efficacy of donepezil and Exelon in Alzheimer’s Disease patients: a 12-weeks multonational study . Presented at the 53rd Annual Meeting of the ФФТб Philadelphia, 5-12 May 2001

118. .Winblad B., Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine) . International Journal of Geriatric Psychiatry . 1999; 14 (2): 135-146

119. .www .medlux .ru, апрель 2009 г .

120. .www .merz .ru/acatinol .php

121. .www .rmbc .ru, 2009 г .

122. .Xie W., Stribley J.A., Chatonnet A., Wilder P.J., Rizzino A., et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase . Journal of Pharmacology and Experimantal Therapeutics . 2000; 293 (3): 896-902

123. .Olin J., Schneider L. Galantamine for Alzheimer’s disease . Cochrane Database of Systematic Reviews 2001; (4): CD001747 . Review . Update in: Cochrane Database of Systematic Reviews . 2002; (3):CD001747 .

124. .Wimo A., Winblad B., Aguero-Torres H., Von Strauss E. The magnitude of dementia occurence in the world . Alzheimer Dis . Assoc . Disord . 2003;17 (2): 63-67

125. .Fratiglioni L., Launer L.J., Andersen K. et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population based cohort . Neurologic Diseases in the Elderly Research Group . Neurology 2000; 54 (11 suppl 5): 10-15

126. .Wimo A., Winblad B., Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005 . Alheimers Dement . 2007; 3: 81-91

127. .Machado J.C., Caramelli P. Treatment of dementia: anything new? Curr . Opin . Psychiatry 2006; 19 (6): 575-580

128. .Imbimbo B.P. Pharmacodinamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease . CNS Drugs 2001; 15 (5): 375-390

129. .Schneider L.S., Anand R., Farlow M.R. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease . Int . J . Geriatr . Psychopharmacol . 1998; 1 (suppl . 1): 26-34

130. .Petersen T.A. Transdermal drug formulations and process development . Pharm . Technol . 2003; (Suppl): 18-21

131. .Winblad B., Machado J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease . Expert Opin . drug Deliv . 2008; 5 (12): 1-10

132. .Lefevre G., Sedek G., Jhee S. et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compare with twice-daily capsules in Alzheimer’s disease patients . Clin . Pharm . Ther . 2008; 83 (1): 106-114

133. .Mercier F., Lefevre G., Huang H.L. et al. Rivastigmine exposure provided by a transdermal patch versus capsules . Curr . Med . Res . Opin . 2007; 23:3199-3204

134. .Lefevre G., Sedek G., Huang H.L. et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application . J . Clin . Pharmacol . 2007 ; 47 (4): 471-478

135. .Winblad B., Cummings J., Andreasen N. et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease — rivastigmine patch versus capsule . Int . J . Geriatr . Psychiatry 2007; 22(5): 456-467

136. .Singh G, et al J Am Geriatr Soc 2005;53:1269–70

137. .Harada ASM, Vanderplas AM . ISPOR annual meeting, May 20–24, 2006, USA


Для цитирования:


Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. 2009;(1):3-28.

For citation:


., ., ., . . Kachestvennaya klinicheskaya praktika. 2009;(1):3-28. (In Russ.)

Просмотров: 58


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)